Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

J&J gets $1.2 billion Arkansas Risperdal judgment tossed out
Yahoo/Reuters
Thursday, March 20, 2014 - 5:21pm
tags:
JNJ, Risperdal, Arkansas
Valeant Targets Corporate ‘Fat’ in Push for Big Leagues
Bloomberg
Thursday, March 20, 2014 - 9:31am
tags:
Valeant Pharmaceuticals, Mike Pearson, restructuring, Bausch & Lomb, M&A
Geron says FDA halts patient enrollment in another cancer trial
Yahoo/Reuters
Thursday, March 20, 2014 - 9:08am
tags:
FDA, Geron, imetelstat, myelofibrosis
Nektar Rises on FDA Notification
Yahoo/Zacks.com
Thursday, March 20, 2014 - 9:07am
tags:
FDA, Nektar, AstraZeneca, Naloxegol, opioid-induced constipation
AstraZeneca Plc After The Patent Cliff
Motley Fool
Thursday, March 20, 2014 - 8:43am
tags:
patents, AstraZeneca, patent cliff
Horizon Pharma acquisition to be significantly accretive, says Stifel
The Fly on the Wall
Thursday, March 20, 2014 - 8:42am
tags:
Horizon Pharma, M&A, Vidara
Merck HIV Drug Strategy Seen Shielding Patent: Corporate India
Bloomberg
Thursday, March 20, 2014 - 8:30am
tags:
HIV, Merck, India, Cipla, Isentress, patents
The FDA's Dilemma With The Opioid Pain Medication Zohydro ER
Forbes
Thursday, March 20, 2014 - 8:28am
tags:
FDA, Zohydro ER, Zogenix, hydrocodone
Glaxo’s Immunotherapy Fails to Help Lung Cancer Patients
Bloomberg
Thursday, March 20, 2014 - 7:10am
tags:
GSK, cancer immunotherapy, MAGE-A3, non-small cell lung cancer
Big Pharma Ramps Up Hep C Strategies
Yahoo/Investors Business Daily
Wednesday, March 19, 2014 - 7:22pm
tags:
hepatitis C, Sovaldi, Gilead Sciences, daclatasvir, Bristol-Myers Squibb, AbbVie, Enanta Pharmaceuticals
New cholesterol guidelines could boost number of US statin users by 12.8 billion: study
First Word Pharma
Wednesday, March 19, 2014 - 7:13pm
tags:
statins, cholesterol
Can Malllinckrodt Keep on Crushing Expectations?
Yahoo/Guru Focus
Wednesday, March 19, 2014 - 7:12pm
tags:
Mallinckrodt
EU looks to speed drug access with staggered approval process
Reuters
Wednesday, March 19, 2014 - 4:13pm
tags:
drug approvals, Europe
Novo reports positive results from phase 3 trial with NovoEight
Reuters
Wednesday, March 19, 2014 - 4:11pm
tags:
Novo Nordisk, NovoEight, hemophilia A
Furiex Diarrhea Drug May Lure Takeover by Salix: Real M&A
Bloomberg
Wednesday, March 19, 2014 - 3:55pm
tags:
Salix, Furiex Pharmaceuticals, M&A, eluxadoline, irritable bowel syndrome
Don't bet on a home-run drug launch, even for power-hitting drugs
Fierce Pharma
Wednesday, March 19, 2014 - 3:50pm
tags:
drug launches, JNJ, Zytiga
Valeant CEO Seeks Acquisitions in High-Growth Health Care
Bloomberg
Wednesday, March 19, 2014 - 3:47pm
tags:
Valeant Pharmaceuticals, M&A, Mike Pearson
The Next Big Biotech Mover: Ariad Pharma
TheStreet.com
Wednesday, March 19, 2014 - 3:45pm
tags:
Ariad Pharmaceuticals
Contrary to popular belief, side-effect reports on new meds keep a steady pace, study finds
Fierce Pharma
Wednesday, March 19, 2014 - 12:02pm
tags:
side effects, FDA
Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals
Motley Fool
Wednesday, March 19, 2014 - 12:01pm
tags:
Horizon Pharma, Prothena, Portola Pharmaceuticals, M&A, Vidara, NEOD001, andexanet alfa

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.